IPOADARx Files for Nasdaq Listing With Three Drugs in ClinicThe siRNA biotech filed its S-1 on September 4 to trade as ADRX, with a pipeline spanning complement disease, hereditary angioedema and stroke prevention, and JPMorgan and Morgan Stanley leading.Sep 4, 2026DEEP DIVE
